Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
March 16 2009 - 6:00AM
PR Newswire (US)
BETHESDA, Md., March 16 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation
and autoimmune diseases, today announced the publication of six
abstracts for poster presentations at the 100th annual meeting of
AACR taking place from April 20-24, 2009, in Denver, Colorado. The
following posters will be presented: 1. Lutterbuese, R. et al.
(2009). Highly efficient lysis of KRAS- and BRAF-mutated human
colon cancer cells by T cell-engaging BiTE antibodies derived from
anti-EGFR antibodies cetuximab and panitumumab. AACR Annual Meeting
2009, abstract no. 3251; to be presented in session 'Immunology 5'
on April 21, 2009, 8:00 AM in Hall B-F, poster section 12. 2.
Muenz, M. et al. (2009). Eradication of colon cancer stem cells by
EpCAM/CD3-bispecific BiTE antibody MT110. AACR Annual Meeting 2009,
abstract no. 3250; to be presented in session 'Immunology 5' on
April 21, 2009, 8:00 AM in Hall B-F, poster section 12. 3. Kischel,
R. et al. (2009). Effector memory T cells make a major contribution
to redirected target cell lysis by T cell-engaging BiTE antibody
MT110. AACR Annual Meeting 2009, abstract no. 3252; to be presented
in session 'Immunology 5' on April 21, 2009, 8:00 AM in Hall B-F,
poster section 12. 4. Oberst, M. et al. (2009). In vitro
pharmacological comparison of a carcinoembryonic antigen (CEA;
CEACAM5; CD66e)/CD3 bispecific cynomolgus-reactive BiTE antibody
(CyS111) biosimilar with the clinical candidate MEDI-565 (MT111).
AACR Annual Meeting 2009, abstract no. 3247; to be presented in
session 'Immunology 5' on April 21, 2009, 8:00 AM in Hall B-F,
poster section 12. 5. Torisu-Itakura, H. et al. (2009). Anti-tumor
activity of a T cell-engaging MCSP-specific BiTE antibody at very
low effector to target ratios: A new approach to treat metastatic
melanoma. AACR Annual Meeting 2009, abstract no. 3248; to be
presented in session 'Immunology 5' on April 21, 2009, 8:00 AM in
Hall B-F, poster section 12. 6. Aigner, M. et al. (2009). Effective
in vitro lysis of human melanoma cell lines by T lymphocytes
redirected with a MCSP/CD3-bispecific single-chain antibody
construct is independent of the expression of tumor-associated
antigens gp100, MART-1, tyrosinase and NY-ESO1. AACR Annual Meeting
2009, abstract no. 4152; to be presented in session 'Immunology 6'
on April 21, 2009, 1:00 PM in Hall B-F, poster section 11.
Abstracts can be accessed at http://www.aacr.org/. About Micromet
Micromet, Inc. (http://www.micromet-inc.com/) is a
biopharmaceutical company with offices in Bethesda, MD and Munich,
Germany. The Company is focused on developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases. The Company's novel antibody technology is based on its
proprietary BiTE(R) antibody platform, representing a new class of
antibodies that specifically activate T cells from the patient's
own immune system to eliminate cancer cells or other disease
related cells. Four of the Company's antibodies are currently in
clinical trials, with the remainder of its product pipeline in
preclinical development. The Company's lead program is a BiTE
antibody known as blinatumomab, or MT103. It is in a phase 2
clinical trial for the treatment of patients with acute
lymphoblastic leukemia and a phase 1 clinical trial for the
treatment of patients with non-Hodgkin's lymphoma. Micromet's
second BiTE antibody in clinical development is MT110, which
targets the epithelial cell adhesion molecule (EpCAM). The Company
owns all rights to MT110, which is currently in a phase 1 clinical
trial for the treatment of patients with solid tumors. The
Company's third clinical stage antibody is adecatumumab, also known
as MT201, a traditional human monoclonal antibody that targets
EpCAM-expressing solid tumors. Micromet is developing adecatumumab
in collaboration with Merck Serono in a phase 1b clinical trial
evaluating adecatumumab in combination with docetaxel for the
treatment of patients with metastatic breast cancer. Micromet
licensed a fourth clinical stage antibody, MT293, to TRACON
Pharmaceuticals, Inc. MT293 is being developed in a phase 1
clinical trial for the treatment of patients with cancer. The
Company's preclinical programs include MT203 being developed in
collaboration with Nycomed. MT203 is a traditional human antibody
neutralizing the activity of granulocyte/macrophage colony
stimulating factor (GM-CSF), which has potential applications in
the treatment of inflammatory and autoimmune diseases, such as
rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet
has granted an exclusive option to Bayer Schering Pharma AG to
license a BiTE antibody against an undisclosed solid tumor target.
Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and
MCSP, respectively, are in different stages of preclinical
development. Forward-Looking Statements This release contains
certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially
different from historical results or from any future results
expressed or implied by such forward-looking statements. These
forward-looking statements include statements regarding the
efficacy, safety and intended utilization of our product
candidates, the development of our BiTE antibody technology, the
return of development and commercialization rights to blinatumomab,
the future development of blinatumomab and a new BiTE antibody
binding to CD19, the conduct, timing and results of future clinical
trials, expectations of the future expansion of our product
pipeline and collaborations, our plans regarding future
presentations of clinical data, our expectations of timing for the
publication of results from our research and development programs,
our ability to draw down on the Committed Equity Financing Facility
with Kingsbridge, and our plans regarding collaborations and other
partnering activities. You are urged to consider statements that
include the words "ongoing," "may," "will," "believes,"
"potential," "expects," "plans," "anticipates," "intends," or the
negative of those words or other similar words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or
clinical trials do not demonstrate safety and/or efficacy in
subsequent clinical trials, the risk that encouraging results from
early research, preclinical studies or clinical trials may not be
confirmed upon further analysis of the detailed results of such
research, preclinical study or clinical trial, the risk that
additional information relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon
further analysis of preclinical or clinical trial data, the risk
that we or our collaborators will not obtain approval to market our
product candidates, the risks associated with reliance on outside
financing to meet capital requirements, and the risks associated
with reliance on collaborators, including MedImmune, Merck Serono,
TRACON and Nycomed, for the funding or conduct of further
development and commercialization activities relating to our
product candidates. These factors and others are more fully
discussed in Micromet's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2008, filed with the SEC on November 6,
2008, as well as other filings by the company with the SEC.
DATASOURCE: Micromet, Inc. CONTACT: US Media, Andrea tenBroek or
Chris Stamm, +1-781-684-0770, , or European Media, Ludger Wess,
+49(40)8816-5964, , or US Investors, Susan Noonan, +1-212-966-3650,
, or European Investors, Ines-Regina Buth, +49(30)2363-2768, Web
Site: http://www.micromet-inc.com/
Copyright